Zurcher Kantonalbank Zurich Cantonalbank Has $433,000 Stock Position in Amylyx Pharmaceuticals, Inc. $AMLX

Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 1,782.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 35,877 shares of the company’s stock after purchasing an additional 33,971 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Amylyx Pharmaceuticals were worth $433,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in AMLX. California State Teachers Retirement System purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $28,000. Legal & General Group Plc purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $47,000. BNP Paribas Financial Markets raised its stake in shares of Amylyx Pharmaceuticals by 433.2% in the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after purchasing an additional 5,904 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Amylyx Pharmaceuticals in the third quarter worth approximately $48,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after purchasing an additional 1,890 shares during the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Mizuho increased their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. Bank of America increased their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Wall Street Zen raised Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Stifel Nicolaus assumed coverage on Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $21.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.56.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $16.01 on Monday. The firm has a market cap of $1.78 billion, a PE ratio of -10.33 and a beta of -0.11. The business has a 50 day moving average of $15.26 and a 200-day moving average of $14.25. Amylyx Pharmaceuticals, Inc. has a 12-month low of $4.20 and a 12-month high of $18.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.01. On average, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.39 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.